Diabetic Retinopathy and Antivascular Endothelial Growth Factor Agents

The exploratory analysis performed by Bressler et al in this issue ofJAMA Ophthalmology expounds on the already compelling results from the Diabetic Retinopathy Clinical Research Network (DRCR.net) Protocol T study. Protocol T provided crucial data comparing the 3 most commonly used antivascular endothelial growth factor (VEGF) agents in the management of diabetic macular edema. The authors use the 2-year prospective data on diabetic macular edema treatment to compare the relative efficacy of aflibercept, ranibizumab, and bevacizumab on another clinically relevant end point: diabetic retinopathy (DR) severity.
Source: JAMA Ophthalmology - Category: Opthalmology Source Type: research